Stephen V Liu, MD (@stephenvliu) 's Twitter Profile
Stephen V Liu, MD

@stephenvliu

Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Co-Host @IASLC Podcast; Chair #TexasLung25 #DCLung25; #HereWeGo

ID: 377425889

linkhttps://www.medstarhealth.org/doctors/stephen-liu-md calendar_today21-09-2011 15:17:53

19,19K Tweet

26,26K Followers

3,3K Following

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo
Stephen V Liu, MD
@stephenvliu

4 months ago

The phase III ETOP 25-23 ADOPT-lung will try to determine the benefit of adjuvant immunotherapy after neoadjuvant chemo-IO, outlined in Lung Cancer Journal. Pts with resectable stage IIA-IIIB NSCLC receive induction durvalumab + chemo, then randomized to 1y of durva vs observation.

The phase III ETOP 25-23 ADOPT-lung will try to determine the benefit of adjuvant immunotherapy after neoadjuvant chemo-IO, outlined in <a href="/LungCaJournal/">Lung Cancer Journal</a>. Pts with resectable stage IIA-IIIB NSCLC receive induction durvalumab + chemo, then randomized to 1y of durva vs observation.